Monte Rosa Therapeutics (GLUE) Earnings Date & Reports

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

GLUE is expected to report earnings to fall 8.21% to -39 cents per share on November 05

Monte Rosa Therapeutics GLUE Stock Earnings Reports

Q3'26

Est.

$-0.39

Q2'26

Missed

by $0.05

Q1'26

Missed

by $0.03

Q4'25

Missed

by $0.10

Q3'25

Beat

by $0.03

The last earnings report on August 06 showed earnings per share of -43 cents, missing the estimate of -37 cents. With 151.16K shares outstanding, the current market capitalization sits at 1.32B.

View a ticker or compare two or three

GLUE

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days